OBJECTIVES: Irritable bowel syndrome (IBS) is a common gastrointestinal condition with a
heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS …

Background & Aims Despite rescue therapy, more than 30% of patients with acute severe
ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase …

Methods All 4 patients with ASUC had a high likelihood of failing IV corticosteroid monotherapy
based on severe Truelove and Witt’s criteria, C-reactive protein (CRP)> 100 mg/L at …

Background Safety of anti-tumour necrosis factor-α (TNFα) therapy in people with a history
of cancer and with an immune-mediated disease is unknown. We aimed to assess the risk of …

Background and Aims Intestinal strictures are a common complication of Crohn’s disease (CD).
Biomarkers of intestinal strictures would assist in their prediction, diagnosis, and …

Background Coronavirus disease-2019 (COVID-19) is a global pandemic. Obesity has been
associated with increased disease severity in COVID-19, and obesity is strongly associated …

Background Dual targeted therapy (DTT) has emerged as an attractive therapeutic option
for select patients with active inflammatory bowel disease (IBD) who are unable to achieve …

Background Fibrosis is the final common pathway to intestinal failure in Crohn’s disease,
but no medical therapies exist to treat intestinal fibrosis. Activated myofibroblasts are key …

Background Infliximab can prevent colectomy in patients hospitalized with acute severe
ulcerative colitis (ASUC). In cases of ASUC, fecal losses of infliximab may lead to low drug levels …

Lay Summary We present a case series of 16 patients with ulcerative colitis who received
upadacitinib after failing tofacitinib. Five patients (36%) achieved steroid-free clinical remission…